[Federal Register Volume 63, Number 127 (Thursday, July 2, 1998)]
[Notices]
[Pages 36235-36236]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-17594]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention
[INFO-98-22]


Proposed Data Collections Submitted for Public Comment and 
Recommendations

    In compliance with the requirement of Section 3506(c)(2)(A) of the 
Paperwork Reduction Act of 1995 for opportunity for public comment on 
proposed data collection projects, the Centers for Disease Control and 
Prevention (CDC) will publish periodic summaries of proposed projects. 
To request more information on the proposed projects or to obtain a 
copy of the data collection plans and instruments, call the CDC Reports 
Clearance Officer on (404) 639-7090.
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques for other 
forms of information technology. Send comments to Seleda Perryman, CDC 
Assistant Reports Clearance Officer, 1600 Clifton Road, MS-D24, 
Atlanta, GA 30333. Written comments should be received within 60 days 
of this notice.

Proposed Project

    1. Gonococcal Isolate Surveillance Project (GISP) (0920-0307)--
Extension--The Division of STD Prevention, National Center for HIV, STD 
and TB Prevention (NCHSTP) is requesting a 3-year extension of OMB 
clearance to continue the Gonococcal Isolate Surveillance Project 
(GISP). The objectives of GISP are: (1) To monitor trends in 
antimicrobial susceptibility of strains of Neisseria gonorrhoeae in the 
United States; and (2) to characterize resistant isolates. GISP 
provides critical surveillance for antimicrobial resistance, allowing 
for informed treatment recommendations. GISP was begun in 1986 as a 
voluntary surveillance project and now involves 5 regional laboratories 
and 26 publicly funded sexually transmitted disease clinics around the 
country. The STD clinics submit up to 25 gonococcal

[[Page 36236]]

isolates per month to the regional laboratories, which measure 
susceptibility to a panel of antibiotics. Limited demographic and 
clinical information corresponding to the isolates are submitted 
directly by the clinics to CDC.
    During 1986-1997, GISP has demonstrated the ability to effectively 
achieve its objectives. The recent emergence of resistance to 
fluoroquinolones, commonly used therapies for gonorrhea, has been 
identified through GISP and makes ongoing surveillance critical. Data 
gathered through GISP are used to alert the public health community to 
changes in antimicrobial resistance in N. gonorrhoeae which may impact 
treatment choices, and to guide recommendations made in CDC's STD 
Treatment Guidelines, which are published every several years. There is 
no cost to the respondents.

----------------------------------------------------------------------------------------------------------------
                                                                      No. of                                    
                   Respondent                         No. of        responses/      Avg. burden    Total burden 
                                                    respondents     respondents      (in hrs.)       (in hrs.)  
----------------------------------------------------------------------------------------------------------------
Laboratory......................................               5            1056           1                5312
Clinic..........................................              26             204           0.166            8846
                                                 ---------------------------------------------------------------
    Total.......................................  ..............  ..............  ..............            6196
----------------------------------------------------------------------------------------------------------------

    2. Tuberculosis Statistics and Program Evaluation Activity, Contact 
Follow-up (CDC 72.16) and Completion of Preventive Therapy (CDC 
72.21)--(0920-0026)--Extension--The National Center for HIV, STD and TB 
Prevention (NCHSTP)--Tuberculosis (TB) is transmitted when contagious 
TB patients aerosolize Mycobacterium tuberculosis and susceptible 
persons (i.e., ``contacts'') are exposed. Some contacts are especially 
endangered by TB if they become infected--children younger than 5 years 
old, and anyone with an illness that weakens the immune system (e.g., 
the acquired immunodeficiency syndrome, AIDS). The prompt evaluation of 
all contacts is crucial for finding early TB cases and latent 
infections. For latent TB infections, treatment with isoniazid 
preventive therapy can prevent new TB cases from developing. 
Evaluation, follow-up, and preventive therapy for contacts comprise the 
most efficient approach for finding and treating recent TB infections 
and preventing future cases. Therefore, it is one of the highest 
priorities for the national TB control strategy, second only to finding 
and treating contagious cases. The local and the state TB control 
programs and CDC use Contact Follow-up (CDC 72.16) and Completion of 
Preventive Therapy (CDC 72.21) to measure progress in achieving the 
national goals for performance in these areas. There is no cost to the 
respondents.

----------------------------------------------------------------------------------------------------------------
                                                                     No. of                                     
                                                     No. of        responses/      Avg. burden/    Total burden 
                     Report                        respondents   respondent (in    response (in      (in hrs.)  
                                                                      hrs.)           hrs.)                     
----------------------------------------------------------------------------------------------------------------
Contact Follow-up (1996),......................             103               2               .5             103
Completion of Preventive Therapy (1995)........             103               2              1               206
    Total......................................  ..............  ..............  ...............             309
----------------------------------------------------------------------------------------------------------------

    Dated: June 26, 1998.
Charles W. Gollmar,
Acting Associate Director for Policy, Planning and Evaluation,Centers 
for Disease Control and Prevention (CDC).
[FR Doc. 98-17594 Filed 7-1-98; 8:45 am]
BILLING CODE 4163-18-P